


Numbio Therapeutics Revenue
Biotechnology Research • • 1-10 Employees
Numbio Therapeutics revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Key Contact at Numbio Therapeutics
Maxime Ranger
Cofounder - CEO
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
| Socials |
Numbio Therapeutics Email Formats
Numbio Therapeutics uses 1 email format. The most common is {first initial} (e.g., j@neurenati.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial} | j@neurenati.com | 100% |
About Numbio Therapeutics
Neurenati Therapeutics is a pioneer biotechnology company based in Montreal. They develop revolutionary treatment for the hirschsprung disease, aiming to regeneration the entérico nervous system and improve intestinal functions. The company was founded in 2020 by two researchers in the academic sector. Neurenati Therapeutics is committed to bringing this therapy to clinical trials.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Numbio Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Numbio Therapeutics has never raised funding before.
Frequently asked questions
4.8
40,000 users



